We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $1.74 · 6 analysts
Stored first · Google News · Yahoo Finance (English)
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Mereo BioPharma | DEF 14A: Definitive information statements - Moomoo
Mereo BioPharma | DEF 14A: Definitive information statements Moomoo
MREO Stockholders Have Opportunity to Lead Mereo BioPharma Group - The National Law Review
MREO Stockholders Have Opportunity to Lead Mereo BioPharma Group The National Law Review
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Gro The National Law Review
MREO Forecast — Price Target — Prediction for 2027 - TradingView
MREO Forecast — Price Target — Prediction for 2027 TradingView
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.01 | — | — | $863.83K | — | Scheduled |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.02 | — | — | $0 | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.03 | — | — | $0 | Reported |
| FY2024 Q3 | 2023. 09. 30. | Time TBD | — | $-0.03 | — | — | $9M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 03. 23. | JP Morgan | — | Downgrade | Overweight → Neutral | — | JP Morgan: Overweight → Neutral |
| 2026. 01. 17. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 01. 13. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2025. 12. 30. | Jefferies | — | Downgrade | Buy → Hold | — | Jefferies: Buy → Hold |
| 2025. 12. 30. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 525,125 | $218.82K | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 187,839 | $61.99K | 0.00% | — | New position |